
(Source: Tilray)
Tilray Brands (TLRY) posted record quarterly revenue of $217.5 million for the second quarter of fiscal year 2026, driven largely by robust international market performance. Revenue rose 3% year-over-year. Distribution operations were particularly strong, up 26% to $85.3 million, supported by competitive pricing strategies, a focus on high-margin products, and favorable exchange rates.
After short-term timing impacts on import and export licenses affected international cannabis operations in the first quarter, the second quarter saw a 36% increase. As global expansion accelerates, Tilray plans to scale back shipments to the Canadian wholesale market following fiscal year 2026, reallocating resources to higher-margin international cannabis opportunities. Management remains optimistic about the parallel growth of distribution and international cannabis businesses, viewing their complementarity as a driver of overall strength.
Tilray’s beverage business faces headwinds in the craft beer segment and near-term pressure from Project 420’s portfolio optimization, including SKU reduction and prioritizing profitability. The company expects that spring product resets by retailers will boost brand visibility and refine the product mix, supporting both revenue and gross margin.
The wellness segment held steady in the second quarter, thanks to value-added innovation and continued growth in Hi-Ball and the Ingredient Channel. However, challenges in the club retail channel slightly offset these gains, prompting the company to implement targeted adjustments.
In the broader industry, Cronos Group (CRON) plans to acquire CanAdelaar B.V.—the largest company in the Netherlands’ adult-use cannabis pilot program—for an initial payment of $67 million, plus future EBITDA-linked cash payments over the next two years. This acquisition aims to establish a strategic foothold in Europe and expand cross-border product reach.
Canopy Growth (CGC) is restructuring its capital through a series of transactions, extending its existing debt maturity to early 2031 and expects to hold approximately C$425 million in cash to support long-term growth.
Analysts set Tilray’s target price range between $9.25 and $22, with an average target of $12.66, reflecting market optimism about its international expansion and business diversification.
To learn more about Web3, click to register: https://www.gate.com/
Tilray’s second-quarter results underscore the positive impact of international cannabis growth and distribution strategies, while beverage and wellness segments continue to face market challenges. As Canadian shipments are adjusted and international business expands, the company’s overall growth outlook remains strong. Analyst target prices indicate a range of $9.25 to $22, and investors should watch international market trends, distribution integration, and industry competition for their influence on valuation and share price.





